Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-40786
Borsig, L (2010). Heparin as an inhibitor of cancer progression. Progress in Molecular Biology and Translational Science, 93:335-349.
Heparin is frequently used for treatment of cancer-associated thromboembolism. Accumulating clinical evidence indicates that cancer patients treated with unfractionated and low-molecular weight heparin survives longer that patients treated by other anticoagulants, especially patients in the early stage of a disease. Experimental analysis from a number of animal models constantly provides evidence about the ability of heparin to attenuate metastasis. The non-anticoagulant activity of heparin on metastasis includes the ability to inhibit cell-cell-interaction through blocking of P- and L-selectin, to inhibit extracellular matrix protease-heparanase, and to inhibit angiogenesis. This chapter summarizes the current experimental evidence on the biology of heparin during cancer progression with the focus on potential mechanism of heparin antimetastatic activity.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > Institute of Physiology|
07 Faculty of Science > Institute of Physiology
|DDC:||570 Life sciences; biology|
|Date:||21 September 2010|
|Deposited On:||21 Jan 2011 11:07|
|Last Modified:||28 Dec 2013 21:39|
|Citations:||Web of Science®. Times Cited: 12|
Scopus®. Citation Count: 17
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page